Adoptive transfer of virus-specific and tumor-specific T cell immunity.
Adoptive transfer of virus-specific and tumor-specific T cell immunity.
复制标题
DOI：
10.1016/j.coi.2009.02.010
复制
发表时间：
2009-04
影响因子：
7
通讯作者：
Riddell SR
中科院分区：
文献类型：
--
作者：
Berger C;Turtle CJ;Jensen MC;Riddell SR
T细胞的过继转移分离或工程化，对病变细胞具有特异性，是人类病毒性和恶性疾病靶向治疗的理想方法。过继性T细胞治疗感染和癌症的治疗潜力很久以前就在啮齿动物模型中得到了证明，但将这种方法转化为有效的临床治疗方法的任务并不容易。精心设计的临床试验评估了抗原特异性T细胞在人体中的转移，并提供了对疗效障碍和改进T细胞治疗策略的见解。改变宿主环境以促进转移T细胞的持久性和功能的重要性，以及选择或设计用于治疗的T细胞的内在特性在体内决定其命运是最近出现的关键问题，并为下一代临床试验的设计提供了信息。
The adoptive transfer of T cells isolated or engineered to have specificity for diseased cells represents an ideal approach for the targeted therapy of human viral and malignant diseases. The therapeutic potential of adoptive T cell therapy for infections and cancer was demonstrated in rodent models long ago, but the task of translating this approach into an effective clinical therapy has not been easy. Carefully designed clinical trials have evaluated the transfer of antigen-specific T cells in humans, and provided insight into the barriers to efficacy and strategies to improve T cell therapy. The importance of altering the host environment to facilitate persistence and function of transferred T cells and intrinsic properties of T cells that are selected or engineered for therapy in determining their fate in vivo are key issues that have recently emerged and are informing the design of the next generation of clinical trials.
登录
查看更多内容
影响因子：
15.9
作者：
Berger, Carolina;Jensen, Michael C.;Riddell, Stanley R.
通讯作者：
Riddell, Stanley R.
DOI：
10.1196/annals.1321.009
发表时间：
2004-01-01
期刊：
GLUCOCORTICOID ACTION: BASIC AND CLINICAL IMPLICATIONS
影响因子：
--
作者：
Franchimont, D
通讯作者：
Franchimont, D
影响因子：
158.5
作者：
Hunder, Naomi N.;Wallen, Herschel;Yee, Cassian
通讯作者：
Yee, Cassian
影响因子：
3.9
作者：
Dudley, ME;Wunderlich, J;Rosenberg, SA
通讯作者：
Rosenberg, SA
影响因子：
20.3
作者：
Einsele, H;Roosnek, E;Hebart, H
通讯作者：
Hebart, H